Magrolimab Falls Off The Fast Track As Gilead Reveals New Clinical Holds
Biktarvy Settlement Totals $1.25bn Up Front, 3% US Bictegravir Royalty
Executive Summary
The company said in its fourth quarter earnings report that it would not seek accelerated approval for the drug, while it also settled an HIV drug-related intellectual property lawsuit with GSK/ViiV.
You may also be interested in...
Gilead’s Magrolimab Hit With Third Clinical Hold, This Time In AML
Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.
Gilead’s Phase III Trial Halt Raises Questions About Magrolimab’s Value
While the myelodysplastic syndrome trial news seems unlikely to read through to other programs, MDS may have been the drug’s biggest market.
Gilead’s Magrolimab Mostly Back On Track As FDA Lifts AML, MDS Holds
The clinical holds, initially announced in January, raised concerns about the company losing its edge in CD47-targeting drugs. Partial holds on the DLBCL and myeloma programs remain in place.